Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

High-Dose Furmonertinib in Patients With EGFR-Mutated NSCLC and Leptomeningeal Metastases: A Prospective Real-World Study.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Jan 2025

Chen Haiyang, Yang Sen, Wang Lili, Wu Yingxi, Wu Yufeng, Ma Shuxiang, He Zhen, Zhang Cuicui, Liu Yang, Tang Haoran, Dong Hang, Wang Qiming

Abstract excerpt

INTRODUCTION: Leptomeningeal metastasis (LM) is one of the most severe complications of NSCLC. Furmonertinib is a pan-EGFR tyrosine kinase inhibitor (TKI) with a high rate of brain penetration and a wide therapeutic window. Here, we evaluated the efficacy and safety of high-dose furmonertinib in patients with EGFR-mutated NSCLC and LM. METHODS: This prospective real-world study included patients with EGFR-mutated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Lung Neoplasms

Share to Meningeal Carcinomatosis

Share to Meningeal Neoplasms

Share to Protein Kinase Inhibitors

Share to Survival Rate

Source

Identifiers

PMID: 39260521
DOI: 10.1016/j.jtho.2024.09.1385

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

High-Dose Furmonertinib in Patients With EGFR-Mutated NSCLC and Leptomeningeal Metastases: A Prospective Real-World Study.PMID 39260521Read ↗

Significant benefit of high-dose furmonertinib in the treatment of leptomeningeal metastases from non-small-cell lung cancer with EGFR ex19Del mutation: Two case reports and a literature reviewSemantic proximity Read ↗

[Efficacy and Safety of High-dose Furmonertinib plus Intrathecal Pemetrexed for EGFR-mutant Non-small Cell Lung Cancer with Leptomeningeal Metastasis].Semantic proximity Read ↗

Furmonertinib combined with bevacizumab in EGFR-TKI-resistant leptomeningeal metastasis: analysis of the CSF ctDNA molecular response and survival outcomes.Semantic proximity Read ↗

Furmonertinib-based triplet therapy improves survival in EGFR-mutant NSCLC with leptomeningeal metastases: a large-scale multicenter retrospective study (FURMO-LM).Semantic proximity Read ↗

High-dose furmonertinib as first-line treatment for untreated EGFR-mutated advanced NSCLC with central nervous system metastases: A phase 2 trial.Semantic proximity Read ↗

High-dose furmonertinib combined with intraventricular chemotherapy as salvage therapy for leptomeningeal metastasis from EGFR exon 20 insertion-mutated lung cancerSemantic proximity Read ↗

Effectiveness of high-dose third-generation EGFR-tyrosine kinase inhibitors in treating EGFR-mutated non-small cell lung cancer patients with leptomeningeal metastasis.Semantic proximity Read ↗

High-dose furmonertinib combined with intraventricular chemotherapy as salvage therapy for leptomeningeal metastasis from EGFR exon 20 insertion-mutated lung cancer.Semantic proximity Read ↗

Furmonertinib in uncommon EGFR-mutated non-small cell lung cancer with central nervous system metastases: A retrospective cohort study.Semantic proximity Read ↗

Combined Furmonertinib and Intrathecal Chemotherapy for Leptomeningeal Metastasis from Non-Small Cell Lung Cancer: Efficacy, Safety, and CSF Drug ConcentrationsSemantic proximity Read ↗

Leptomeningeal Metastases in Non-small Cell Lung Cancer: Optimal Systemic Management in NSCLC With and Without Driver Mutations.Semantic proximity Read ↗

Real-world survival of EGFR-mutated NSCLC with leptomeningeal metastases: prognostic impact of TKIs and local multidisciplinary treatment from the CLM-tree registrySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.